Entyvio and Colitis microscopic - a phase IV clinical study of FDA data

Summary:

Colitis microscopic is reported as a side effect among people who take Entyvio (vedolizumab), especially for people who are male, 60+ old, also take Prednisolone, and have Enterocolitis.

The phase IV clinical study analyzes which people have Colitis microscopic when taking Entyvio. It is created by eHealthMe based on reports of 23,685 people who have side effects when taking Entyvio from the FDA, and is updated regularly.

What is Entyvio?

Entyvio has active ingredients of vedolizumab. It is often used in crohn's disease. eHealthMe is studying from 23,827 Entyvio users. Check the latest studies of Entyvio.

What is Colitis microscopic?

Colitis microscopic (inflammation of colon with diarrhoea and abdominal cramps) is found to be associated with 376 drugs and 348 conditions by eHealthMe. Check the latest studies of Colitis microscopic.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

23,685 people reported to have side effects when taking Entyvio.
Among them, 17 people (0.07%) have Colitis microscopic.

Could Entyvio cause Colitis microscopic?

Among these 17 people:

What is the gender of people who have Colitis microscopic when taking Entyvio? *

female: 47.06 %
male: 52.94 %

What is the age of people who have Colitis microscopic when taking Entyvio? *

What are other drugs people take besides Entyvio? *

What are other side effects people have besides Colitis microscopic? *

Diarrhea: 10 people, 58.82%
Apoptosis: 7 people, 41.18%
Drug Ineffective: 7 people, 41.18%
Inflammation: 7 people, 41.18%
Escherichia Urinary Tract Infection (urinary tract infection by escherichia coli): 7 people, 41.18%
Intestinal Obstruction: 7 people, 41.18%
Erosive Duodenitis (a condition that affects the wall of the small intestine): 7 people, 41.18%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 7 people, 41.18%
Lymphocyte Count Increased: 7 people, 41.18%
Enteritis (inflammation of the small intestine): 7 people, 41.18%

What are the existing conditions these people have? *

Enterocolitis (inflammation of the digestive tract, involving enteritis of the small intestine and colitis of the colon): 7 people, 41.18%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 4 people, 23.53%
Osteoporosis Post-Menopausal (weak bone with possibility to break after stopped menstrual cycles): 3 people, 17.65%
Malignant Melanoma (skin cancer rises from melancytes): 3 people, 17.65%
Urinary Incontinence (inability to control the flow of urine and involuntary urination): 1 person, 5.88%
Swelling: 1 person, 5.88%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 1 person, 5.88%
Primary Immunodeficiency Syndrome: 1 person, 5.88%
Neuropathy Peripheral (surface nerve damage): 1 person, 5.88%
Nausea (feeling of having an urge to vomit): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Entyvio and have Colitis microscopic?

- Check whether Colitis microscopic is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Entyvio:

Entyvio (23,827 reports)

Browse all side effects of Entyvio:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Colitis microscopic:

Colitis microscopic (376 drugs)

Browse all the conditions that are associated with Colitis microscopic:

Colitis microscopic (348 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on vedolizumab (the active ingredients of Entyvio) and Entyvio (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.